In less than three months, the FDA will decide on approving MDMA for treating PTSD, potentially marking the first Schedule I psychedelic with medical use. Other psychedelics are also being researched for various conditions. The FDA will review the effectiveness and safety of MDMA-assisted psychotherapy for PTSD, considering blinding issues and expectancy bias in trials. Safety concerns include cardiovascular effects and the potential for psychological distress. Therapeutic practices and trial populations are also under scrutiny. Advocates argue for the urgent need for new PTSD treatments, particularly for veterans. The FDA must assess if the benefits of MDMA therapy outweigh the risks for the general population.
Source link
MDMA therapy for PTSD faces crucial FDA panel meeting
